Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: immune checkpoint protein inhibitors - Aurigene Oncology

Drug Profile

Research programme: immune checkpoint protein inhibitors - Aurigene Oncology

Alternative Names: AUNP-12; AUR-012; NP-12 - Aurigene Oncology; PD-1 peptide antagonist - Aurigene Oncology; PDCD-1 protein inhibitors - Aurigene Oncology; TIGIT/ PD-L1 dual inhibitors

Latest Information Update: 28 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Aurigene Oncology
  • Class Antineoplastics; Peptides; Small molecules
  • Mechanism of Action Programmed cell death 1 receptor antagonists; Programmed cell death-1 ligand-1 inhibitors; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer
  • Discontinued Bacterial infections

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for preclinical development in Cancer in India (PO)
  • 04 Jun 2021 Discontinued - Preclinical for Bacterial infections in India (Parenteral) (Aurigene Discovery Technologies, May 2021) (Pierre Fabre's pipeline, June 2021)
  • 04 Jun 2021 Discontinued - Preclinical for Cancer in India (SC) (Aurigene Discovery Technologies, May 2021) (Pierre Fabre's pipeline, June 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top